20980-22-7
Chemical Structure
2-(1-Piperazinyl)pyrimidine
- CAS No.: 20980-22-7
- Formula:C8H12N4
- Molecular Weight:164.21
IUPAC Name: 2-(piperazin-1-yl)pyrimidine
InChIKey: MRBFGEHILMYPTF-UHFFFAOYSA-N
SMILES: N1(C2=NC=CC=N2)CCNCC1
Biological Activity: 2-(1-Piperazinyl)pyrimidine is an orally effective α2-adrenoceptor antagonist and 5-HT1A receptor agonist. 2-(1-Piperazinyl)pyrimidine is an in vivo metabolite related to buspirone. 2-(1-Piperazinyl)pyrimidine modulates excitatory synaptic transmission in the hippocampus and the release of monoamine transmitters such as norepinephrine and 5-HT by blocking α2-adrenoceptor and activating 5-HT1A Receptor. 2-(1-Piperazinyl)pyrimidine is used in research on psychiatric disorders such as anxiety and depression[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
2-(1-Piperazinyl)pyrimidine | 99.94% | 2-(1-Piperazinyl)pyrimidine is an orally effective α2-adrenoceptor antagonist and 5-HT1A receptor agonist. 2-(1-Piperazinyl)pyrimidine is an in vivo metabolite related to buspirone. 2-(1-Piperazinyl)pyrimidine modulates excitatory synaptic transmission in the hippocampus and the release of monoamine transmitters such as norepinephrine and 5-HT by blocking α2-adrenoceptor and activating 5-HT1A Receptor. 2-(1-Piperazinyl)pyrimidine is used in research on psychiatric disorders such as anxiety and depression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-(1-Piperazinyl)pyrimidine (Standard) | 99.95% | 2-(1-Piperazinyl)pyrimidine Standard is the analytical standard of 2-(1-Piperazinyl)pyrimidine (HY-W004464). This product is intended for research and analytical applications. 2-(1-Piperazinyl)pyrimidine is an orally effective α2-adrenoceptor antagonist and 5-HT1A receptor agonist. 2-(1-Piperazinyl)pyrimidine is an in vivo metabolite related to buspirone. 2-(1-Piperazinyl)pyrimidine modulates excitatory synaptic transmission in the hippocampus and the release of monoamine transmitters such as norepinephrine and 5-HT by blocking α2-adrenoceptor and activating 5-HT1A Receptor. 2-(1-Piperazinyl)pyrimidine is used in research on psychiatric disorders such as anxiety and depression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-(1-Piperazinyl)pyrimidine-d8 | 2-(1-Piperazinyl)pyrimidine-d8 is the deuterated-labeled 2-(1-Piperazinyl)pyrimidine (HY-W004464). 2-(1-Piperazinyl)pyrimidine is an orally effective α2-adrenoceptor antagonist and 5-HT1A receptor agonist. 2-(1-Piperazinyl)pyrimidine is an in vivo metabolite related to buspirone. 2-(1-Piperazinyl)pyrimidine modulates excitatory synaptic transmission in the hippocampus and the release of monoamine transmitters such as norepinephrine and 5-HT by blocking α2-adrenoceptor and activating 5-HT1A Receptor. 2-(1-Piperazinyl)pyrimidine is used in research on psychiatric disorders such as anxiety and depression. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gobbi M, et al. Antagonist properties of 1-(2-pyrimidinyl)piperazine at presynaptic alpha 2-adrenoceptors in the rat brain. European journal of pharmacology. 1990 May 03;180(1):183-6.
- [2]. Bianchi G, et al. The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). European journal of pharmacology. 1988 Jul 14;151(3):365-71.
- [3]. Gower AJ, et al. Alpha 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat. European journal of pharmacology. 1988 Oct 11;155(1-2):129-37.
- [4]. Zhang L, et al. Carboxy group derivatization for enhanced electron-transfer dissociation mass spectrometric analysis of phosphopeptides. Proteomics. 2009 Aug;9(16):4093-7.
- [5]. Manahan-Vaughan D, et al. The azapirone metabolite 1-(2-pyrimidinyl)piperazine depresses excitatory synaptic transmission in the hippocampus of the alert rat via 5-HT1A receptors. European journal of pharmacology. 1995 Dec 29;294(2-3):617-24.
